Welcome to our dedicated page for Guardian Pharmacy Services SEC filings (Ticker: GRDN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Guardian Pharmacy Services, Inc. (NYSE: GRDN), a long-term care pharmacy services company based in Atlanta, Georgia. Through these filings, investors can review how Guardian reports its financial condition, results of operations, and other material events.
Guardian’s recent SEC activity includes multiple Current Reports on Form 8-K. These filings have covered topics such as quarterly financial results, reiteration of financial guidance and preliminary outlook, and the furnishing of investor presentations used at healthcare conferences and in meetings with analysts and other interested parties. Certain 8-Ks also describe lock-up agreements with holders of Class A and Class B common stock following the company’s initial public offering.
The company’s filings confirm that its Class A common stock, par value $0.001 per share, is registered under Section 12(b) of the Exchange Act and trades on the New York Stock Exchange under the symbol GRDN. Guardian uses its periodic reports, including the Annual Report on Form 10-K and Quarterly Reports on Form 10-Q (not reproduced here), to present GAAP financial statements and to discuss risk factors affecting its business.
Guardian also explains in its filings and related press releases how it uses non-GAAP measures such as Adjusted EBITDA, Adjusted Net Income, Adjusted EPS, and Adjusted SG&A, and provides reconciliations to the most directly comparable GAAP measures in its full reports. These documents give additional context on how the company evaluates its core operating performance.
On this page, Stock Titan surfaces Guardian’s SEC filings as they are made available on EDGAR and pairs them with AI-generated summaries to help readers understand the key points of each document, from earnings-related 8-Ks to other material disclosures.
Guardian Pharmacy Services, Inc. reported the initial holdings of Senior Vice President of Sales Richard Eakins. He directly holds 98,878 shares of Class A common stock and 36,052 shares of Class B common stock that automatically convert into Class A common stock on September 27, 2026 on a one-for-one basis.
He also holds a stock option for 25,000 shares of Class A common stock with a $32.59 exercise price that vests in full on March 13, 2029. Footnotes state his position also includes 5,063 and 4,476 restricted stock units that will settle in Class A shares upon vesting in 2028 and 2029.
Guardian Pharmacy Services, Inc. executive William Franklin Mudd, Senior Vice President of Finance, filed an initial statement of ownership as a reporting insider. He directly holds 98,465 shares of Class A common stock and 38,282 shares of Class B common stock that convert into Class A on September 27, 2026 on a one-for-one basis.
He also holds stock options covering 25,000 shares of Class A common stock with a $34.59 exercise price, vesting and becoming exercisable in full on February 11, 2029. In addition, his position includes 7,594 and 4,476 restricted stock units that vest on February 14, 2028 and March 1, 2029, respectively, each settling one-for-one in Class A shares.
Guardian Pharmacy Services, Inc. officer Douglas Towns reported his initial equity holdings. He directly holds 89,556 shares of Class A common stock and 23,450 shares of Class B common stock that automatically convert into Class A on a one-for-one basis on September 27, 2026. He also holds stock options covering 25,000 shares of Class A at an exercise price of $34.59 per share, vesting in full on February 11, 2029 and expiring in 2036, plus 7,594 and 4,476 restricted stock units scheduled to vest on February 14, 2028 and March 1, 2029, respectively.
Guardian Pharmacy Services, Inc. officer Martin David Norman filed an initial ownership report showing direct equity stakes in the company. He holds 101,040 shares of Class A common stock and Class B common stock convertible one-for-one into 39,865 Class A shares on September 27, 2026.
Norman also holds a stock option for 25,000 Class A shares at an exercise price of $34.59 per share, expiring in 2036 and scheduled to vest in full on February 11, 2029. Footnotes additionally describe 7,594 and 4,476 restricted stock units that will each settle one-for-one into Class A shares upon vesting in 2028 and 2029.
Guardian Pharmacy Services, Inc. executive Chris Crisafulli reports existing equity holdings in a Form 3 filing. The filing lists 55,469 shares of Class A common stock held directly and 18,931 shares of Class B common stock that convert into Class A on a one-for-one basis on September 27, 2026.
The report also discloses equity-based awards: 7,594 and 4,476 restricted stock units that vest on February 14, 2028 and March 1, 2029, respectively, settling in Class A shares, plus a stock option for 25,000 Class A shares at an exercise price of $34.59 per share that vests in full on February 11, 2029 and expires on February 11, 2036.
Guardian Pharmacy Services, Inc. (GRDN) executive Jeffrey Tuch has filed an initial ownership report showing his equity stake in the company. He directly holds 176,269 shares of Class A common stock and 55,578 shares of Class B common stock that automatically convert into Class A on September 27, 2026. He also holds stock options for 25,000 Class A shares at an exercise price of $34.59 per share, expiring on February 11, 2036, which vest on February 11, 2029. In addition, his position includes 5,063 and 4,476 restricted stock units that vest on February 14, 2028 and March 1, 2029, respectively, each settling one-for-one in Class A shares.
Guardian Pharmacy Services, Inc. officer Robert Weir reported his initial ownership of company equity. He directly holds 79,883 shares of Class A common stock and 23,450 shares of Class B common stock that automatically convert into Class A on September 27, 2026 on a one-for-one basis.
He also holds stock options covering 25,000 shares of Class A common stock with an exercise price of $34.59 per share, which vest and become exercisable in full on February 11, 2029. In addition, his position includes 5,063 and 4,476 restricted stock units that settle one-for-one into Class A shares upon full vesting on February 14, 2028 and March 1, 2029, respectively.
Guardian Pharmacy Services, Inc. investor Pharmacy Investors, LLC converted derivative holdings into common stock. On March 28, 2026, it exercised a derivative position covering 1,413,939 shares of Class B common stock, receiving 1,413,939 shares of Class A common stock at a stated exercise price of $0.00 per share. The company’s charter provides that the Class B shares automatically convert into Class A shares on a one-for-one basis in substantially equal tranches on March 28, 2026 and September 27, 2026. Following this transaction, Pharmacy Investors, LLC directly holds 2,449,867 shares of Class A common stock. No open derivative position remains disclosed in this filing.
Guardian Pharmacy Services director and 10% owner William E. Bindley, through Bindley Capital Partners I, LLC, exercised a derivative position so that 6,100,175 shares of Class B common stock automatically converted into the same number of Class A shares on March 28, 2026.
This automatic one-for-one conversion is described in the company’s Amended and Restated Certificate of Incorporation, which provides for substantially equal tranches on March 28, 2026 and September 27, 2026. Following the transaction, Bindley Capital Partners I, LLC indirectly held 10,569,491 shares of Class A common stock.
Guardian Pharmacy Services, Inc. executive Forbes Kendall reported an automatic conversion of derivative shares into common stock. On March 28, 2026, 608,570 shares of Class B Common Stock converted on a one-for-one basis into 608,570 shares of Class A Common Stock at a conversion price of $0.00 per share. This reflects the first of two substantially equal tranches scheduled under the company’s Amended and Restated Certificate of Incorporation, with the second tranche set for September 27, 2026. Following this transaction, Kendall directly holds 1,061,826 shares of Class A common stock, and there are no remaining derivative positions shown in this filing.